Clarivate’s ‘drugs to watch’ list signals high prices to come
11-02-2020
Antitrust regulators to increase scrutiny of biosimilar deals
04-02-2020
Jarretera / Shutterstock.com
US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
FDA, FTC, US Food and Drug Administration, Stephen Han, Federal Trade Commission, Joe Simons, biologics, biosimilars, antitrust
